Printer Friendly

CEPHALON'S SMALL PEPTIDES SHOW PROMISING PRECLINICAL RESULTS FOR THE TREATMENT OF RETINOPATHY

 CEPHALON'S SMALL PEPTIDES SHOW PROMISING PRECLINICAL
 RESULTS FOR THE TREATMENT OF RETINOPATHY
 WEST CHESTER, Pa., May 4 /PRNewswire/ -- Cephalon, Inc. (NASDAQ: CEPH) today reported preclinical data on the activity of novel small-peptide fragments of insulin-like growth factor-II (IGF-II) in promoting the survival of retinal photoreceptor cells essential to normal vision. As presented by Donna Bozyczko-Coyne, Ph.D., senior scientist at the 1992 Association for Research in Vision and Ophthalmology (ARVO) meeting, Sarasota, Fla., in vitro studies have demonstrated dose-dependent increases in survival of retinal cells after application of small-molecule portions of IGF-II.
 Diseases characterized by the loss of photoreceptor cells, which may respond to the administration of Cephalon's small molecules, include age-related macular degeneration, affecting approximately 2 million people in the United States, and inherited retinopathies, with a patient population of 70,000. Currently, there are no effective therapies for retinopathies, which can result in loss of vision and eventual blindness. To treat these diseases, Cephalon is developing small peptides that are designed to cross the blood-brain barrier.
 "Our program in retinopathy is a good example of the productive discovery process at Cephalon," said Frank Baldino Jr., Ph.D., president and chief executive officer of Cephalon, Inc. "Six months ago, the idea of a program to study photoreceptor cell degeneration was at its inception. Today, we have a series of lead compounds and positive data."
 Cephalon, Inc., founded in 1987, is a neuroscience company focused on small-molecule therapeutics for the treatment of neurodegenerative diseases. Through a broad-based approach encompassing neurobiology, medicinal chemistry and recombinant DNA technology, Cephalon is developing novel molecules that can be administered via conventional means. The company's most advanced programs to prevent neuronal death are targeting stroke, amyotrophic lateral sclerosis (ALS) and Alzheimer's disease.
 -0- 5/4/92
 /CONTACT: Nicole Vitullo of Cephalon, 215-344-0200, or Karen Bergman of Burns McClellan, 212-545-1919, for Cephalon/
 (CEPH) CO: Cephalon, Inc. ST: Pennsylvania IN: MTC SU:


PS-OS -- NY036 -- 5938 05/04/92 10:40 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 4, 1992
Words:324
Previous Article:KAUFMAN AND BROAD REPORTS RECORD SECOND QUARTER NET ORDERS IN CALIFORNIA
Next Article:3COM'S ERIC BENHAMOU TO DELIVER KEYNOTE ADDRESS AT COMNET SAN FRANCISCO, JULY 20-23, 1992


Related Articles
CEPHALON BRIEFS STOCKHOLDERS ON RESEARCH PROGRESS, NEW DEVELOPMENTS
CEPHALON INITIATES FIRST HUMAN CLINICAL TRIAL FOR MYOTROPHIN TO TREAT LOU GEHRIG'S DISEASE
CEPHALON AND KYOWA HAKKO KOGYO ANNOUNCE COLLABORATION
CEPHALON AND SCHERING-PLOUGH CONTINUE RESEARCH COLLABORATION
CEPHALON FILES INVESTIGATIONAL NEW DRUG APPLICATION FOR THE USE OF MYOTROPHIN FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
CEPHALON REPORTS PROGRESS ON ALZHEIMER'S DISEASE RESEARCH
CEPHALON REPORTS PROGRESS ON ALZHEIMER'S DISEASE RESEARCH
CEPHALON, INC. PRESENTS PROMISING DATA ON SMALL MOLECULE NEUROTROPHIC FACTORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
CEPHALON, INC. PRESENTS PROMISING DATA ON SMALL MOLECULE NEUROTROPHIC FACTORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
CEPHALON PRESENTS SIGNIFICANT DISCOVERY IN ALZHEIMER'S DISEASE PROGRAM

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters